NEW YORK (AP) — In a story September 29, 2020, which included information about Myovant Sciences’ potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study. The drug failed to meet one of its goals within a broader late-stage study.
Before you consider Xylo Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylo Technologies wasn't on the list.
While Xylo Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
